The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that ...

Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Australia's Therapeutic Goods Administration (TGA) recently issued a safety alert requiring extra warnings to be included ...

MILLIONS of Brits with asthma are potentially risking their lives by not using their inhaler properly, UK experts have warned The UK has one worst death rates from the lung condition in ...

In Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, the Federal Circuit jumped on the bandwagon ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4) receptor blockers. The medication is not available in a biosimilar version. Read on for more information about Dupixent.

Apart from Victoza, which was approved for Type 2 diabetes in 2010, liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy ...